Abstract
Some of the ATP-binding cassette (ABC) transporters like P-glycoprotein (P-gp; ABCB1, MDR1), BCRP (ABCG2) and MRPs (ABCCs) that are present at the blood-brain barrier (BBB) influence the brain pharmacokinetics (PK) of their substrates by restricting their uptake or enhancing their clearance from the brain into the blood, which has consequences for their CNS pharmacodynamics (PD). Opioid drugs have been invaluable tools for understanding the PK-PD relationships of these ABC-transporters. The effects of morphine, methadone and loperamide on the CNS are modulated by P-gp. This review examines the ways in which other opioid drugs and some of their active metabolites interact with ABC transporters and suggests new mechanisms that may be involved in the variability of the response of the CNS to these drugs like carrier-mediated system belonging to the solute carrier (SLC) superfamily. Exposure to opioids may also alter the expression of ABC transporters. P-gp can be overproduced during morphine treatment, suggesting that the drug has a direct or, more likely, an indirect action. Variations in cerebral neurotransmitters during exposure to opioids and the release of cytokines during pain could be new endogenous stimuli affecting transporter synthesis. This review concludes with an analysis of the pharmacotherapeutic and clinical impacts of the interactions between ABC transporters and opioids.
Keywords: Blood-brain barrier, opioids, morphine, addiction, drugs of abuse, ABC transporters, P-glycoprotein, SLC transporters, tolerance, xenobiotic transporters
Current Pharmaceutical Design
Title: Opioid Transport by ATP-Binding Cassette Transporters at the Blood-Brain Barrier: Implications for Neuropsychopharmacology
Volume: 17 Issue: 26
Author(s): Nicolas Tournier, Xavier Decleves, Bruno Saubamea, Jean-Michel Scherrmann and Salvatore Cisternino
Affiliation:
Keywords: Blood-brain barrier, opioids, morphine, addiction, drugs of abuse, ABC transporters, P-glycoprotein, SLC transporters, tolerance, xenobiotic transporters
Abstract: Some of the ATP-binding cassette (ABC) transporters like P-glycoprotein (P-gp; ABCB1, MDR1), BCRP (ABCG2) and MRPs (ABCCs) that are present at the blood-brain barrier (BBB) influence the brain pharmacokinetics (PK) of their substrates by restricting their uptake or enhancing their clearance from the brain into the blood, which has consequences for their CNS pharmacodynamics (PD). Opioid drugs have been invaluable tools for understanding the PK-PD relationships of these ABC-transporters. The effects of morphine, methadone and loperamide on the CNS are modulated by P-gp. This review examines the ways in which other opioid drugs and some of their active metabolites interact with ABC transporters and suggests new mechanisms that may be involved in the variability of the response of the CNS to these drugs like carrier-mediated system belonging to the solute carrier (SLC) superfamily. Exposure to opioids may also alter the expression of ABC transporters. P-gp can be overproduced during morphine treatment, suggesting that the drug has a direct or, more likely, an indirect action. Variations in cerebral neurotransmitters during exposure to opioids and the release of cytokines during pain could be new endogenous stimuli affecting transporter synthesis. This review concludes with an analysis of the pharmacotherapeutic and clinical impacts of the interactions between ABC transporters and opioids.
Export Options
About this article
Cite this article as:
Tournier Nicolas, Decleves Xavier, Saubamea Bruno, Scherrmann Jean-Michel and Cisternino Salvatore, Opioid Transport by ATP-Binding Cassette Transporters at the Blood-Brain Barrier: Implications for Neuropsychopharmacology, Current Pharmaceutical Design 2011; 17 (26) . https://dx.doi.org/10.2174/138161211797440203
DOI https://dx.doi.org/10.2174/138161211797440203 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Implications of Prion Protein Biology
Current Neurovascular Research The Endocannabinoid System May Modulate Sleep Disorders in Aging
Current Neuropharmacology Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Structure-Affinity-Relationship Study of Bicyclic σ Receptor Ligands
Central Nervous System Agents in Medicinal Chemistry Rapid Quantification of Neurons and Stem/Progenitor Cells in the Adult Mouse Brain by Flow Cytometry
Letters in Drug Design & Discovery Advanced Platelet-Rich Fibrin Extract Treatment Promotes the Proliferation and Differentiation of Human Adipose-Derived Mesenchymal Stem Cells through Activation of Tryptophan Metabolism
Current Stem Cell Research & Therapy Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Anti-Inflammatory Treatments for Chronic Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Analysis of Electrical Brain Waves in Neurotoxicology: Gamma- Hydroxybutyrate
Current Neuropharmacology ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry Isoform Selective Voltage-Gated Sodium Channel Modulators and the Therapy of Pain
Current Medicinal Chemistry Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy
Current Neuropharmacology Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research